{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T02:13:07Z","timestamp":1776823987830,"version":"3.51.2"},"reference-count":145,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jacl.2025.12.003","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T08:09:50Z","timestamp":1764835790000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Lipoprotein(a) at the crossroads of inflammation and atherosclerosis in rheumatoid arthritis: A narrative review"],"prefix":"10.1016","author":[{"given":"Yuliasih","family":"Yuliasih","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5737-2655","authenticated-orcid":false,"given":"Betty","family":"Rachma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5730-2013","authenticated-orcid":false,"given":"Henry","family":"Sutanto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2025.12.003_bib0001","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3390\/ijms23020905","article-title":"Rheumatoid arthritis: pathogenic roles of diverse immune cells","volume":"23","author":"Jang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jacl.2025.12.003_bib0002","article-title":"Association of cardiovascular risks in rheumatoid arthritis patients: management, treatment and future perspectives","volume":"8","author":"Johri","year":"2023","journal-title":"Health Sci Rev"},{"key":"10.1016\/j.jacl.2025.12.003_bib0003","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.025467","article-title":"Relationship between risk of atherosclerotic cardiovascular disease, inflammation, and coronary microvascular dysfunction in rheumatoid arthritis","volume":"11","author":"Weber","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2025.12.003_bib0004","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1136\/heartjnl-2019-316193","article-title":"Cardiovascular risk factors and outcomes in early rheumatoid arthritis: a population-based study","volume":"106","author":"Nikiphorou","year":"2020","journal-title":"Heart"},{"key":"10.1016\/j.jacl.2025.12.003_bib0005","first-page":"42","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2025.12.003_bib0006","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s11883-024-01215-5","article-title":"Lipoprotein(a) -related inflammatory imbalance: a novel horizon for the development of atherosclerosis","volume":"26","author":"Qin","year":"2024","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.jacl.2025.12.003_bib0007","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3899\/jrheum.210366","article-title":"Is the gap in incidence of cardiovascular events in rheumatoid arthritis really closing?","volume":"48","author":"Bathon","year":"2021","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jacl.2025.12.003_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1190607","article-title":"Lipid metabolism and rheumatoid arthritis","volume":"14","author":"Lei","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jacl.2025.12.003_bib0009","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-030651","article-title":"Levels of lipoprotein (a) in patients with coronary artery disease with and without inflammatory rheumatic disease: a cross-sectional study","volume":"9","author":"Holm","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.jacl.2025.12.003_bib0010","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.3390\/jcm12072529","article-title":"Lipoprotein (a) inflammation, and atherosclerosis","volume":"12","author":"Di Fusco","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacl.2025.12.003_bib0011","doi-asserted-by":"crossref","first-page":"368","DOI":"10.31616\/asj.2018.0178","article-title":"Angiopoietin-like protein 2 induces synovial inflammation in the facet joint leading to degenerative changes via interleukin-6 secretion","volume":"13","author":"Sugimoto","year":"2019","journal-title":"Asian Spine J"},{"key":"10.1016\/j.jacl.2025.12.003_bib0012","doi-asserted-by":"crossref","unstructured":"Robinson, G; Pineda-Torra, I; Ciurtin, C; Jury, EC Lipid metabolism in autoimmune rheumatic disease: implications for modern and conventional therapies. J Clin Invest 132, e148552, doi:10.1172\/JCI148552.","DOI":"10.1172\/JCI148552"},{"key":"10.1016\/j.jacl.2025.12.003_bib0013","doi-asserted-by":"crossref","first-page":"969","DOI":"10.3390\/molecules28030969","article-title":"Lipoprotein(a) in atherosclerotic diseases: from pathophysiology to diagnosis and treatment","volume":"28","author":"Lampsas","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.jacl.2025.12.003_bib0014","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.122.003737","article-title":"Value of genetic testing for lipoprotein(a) variants","volume":"15","author":"Langsted","year":"2022","journal-title":"Circ Genomic Precis Med"},{"key":"10.1016\/j.jacl.2025.12.003_bib0015","doi-asserted-by":"crossref","unstructured":"Borovac, JA Lipoprotein(a), a moving target: from the primary to secondary prevention of atherothrombotic events. 2020, doi:10.1136\/heartjnl-2020-316919.","DOI":"10.1136\/heartjnl-2020-316919"},{"key":"10.1016\/j.jacl.2025.12.003_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.841545","article-title":"Modified lipoproteins induce arterial wall inflammation during atherogenesis","volume":"9","author":"Lorey","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacl.2025.12.003_bib0017","doi-asserted-by":"crossref","first-page":"6040","DOI":"10.3390\/jcm11206040","article-title":"Lipoprotein(a): evidence for role as a causal risk factor in cardiovascular disease and emerging therapies","volume":"11","author":"Bhatia","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacl.2025.12.003_bib0018","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.3390\/ijms20184633","article-title":"Effects of Tocilizumab, an anti-interleukin-6 receptor antibody, on serum lipid and adipokine levels in patients with rheumatoid arthritis","volume":"20","author":"Hoffman","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jacl.2025.12.003_bib0019","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/S0002-9440(10)62531-X","article-title":"Plasma apolipoprotein(a) co-deposits with fibrin in inflammatory arthritic joints","volume":"159","author":"Busso","year":"2001","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jacl.2025.12.003_bib0020","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s42003-023-04897-w","article-title":"Multi-omics delineation of cytokine-induced endothelial inflammatory states","volume":"6","author":"Groten","year":"2023","journal-title":"Commun Biol"},{"key":"10.1016\/j.jacl.2025.12.003_bib0021","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.54754","article-title":"Metabolic response of blood vessels to TNF\u03b1","volume":"9","author":"Junaid","year":"2020","journal-title":"eLife"},{"key":"10.1016\/j.jacl.2025.12.003_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.641734","article-title":"Role of interleukin-6 in vascular health and disease","volume":"8","author":"Villar-Fincheira","year":"2021","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.jacl.2025.12.003_bib0023","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.3389\/fimmu.2020.01442","article-title":"Secreted osteoclastogenic factor of activated T cells (SOFAT) is associated with rheumatoid arthritis and joint pain: initial evidences of a new pathway","volume":"11","author":"Napimoga","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jacl.2025.12.003_bib0024","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.3390\/antiox11061153","article-title":"The role of reactive oxygen species in the rheumatoid arthritis-associated synovial microenvironment","volume":"11","author":"Wang","year":"2022","journal-title":"Antioxidants"},{"key":"10.1016\/j.jacl.2025.12.003_bib0025","doi-asserted-by":"crossref","first-page":"466","DOI":"10.12688\/f1000research.112921.1","article-title":"Accelerated atherosclerosis in rheumatoid arthritis: a systematic review","volume":"11","author":"Raj","year":"2022","journal-title":"F1000Research"},{"key":"10.1016\/j.jacl.2025.12.003_bib0026","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.freeradbiomed.2017.02.035","article-title":"The effect of oxidized phospholipids on phenotypic polarization and function of macrophages","volume":"111","author":"Serbulea","year":"2017","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.jacl.2025.12.003_bib0027","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.655477","article-title":"A tale of two immune cells in rheumatoid arthritis: the crosstalk between macrophages and T cells in the synovium","volume":"12","author":"Tu","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jacl.2025.12.003_bib0028","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3390\/biomedicines10010133","article-title":"Postprandial hyperlipidemia: association with inflammation and subclinical atherosclerosis in patients with rheumatoid arthritis","volume":"10","author":"Mena-V\u00e1zquez","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.jacl.2025.12.003_bib0029","doi-asserted-by":"crossref","unstructured":"Liao, KP Through the looking glass of rheumatoid arthritis to study inflammation and high-density lipoprotein. 2017, doi:10.1136\/heartjnl-2016-310764.","DOI":"10.1136\/heartjnl-2016-310764"},{"key":"10.1016\/j.jacl.2025.12.003_bib0030","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.4103\/0975-7406.155767","article-title":"Comparative study on serum lipoprotein (a) and lipid profile between rheumatoid arthritis patients and normal subjects","volume":"7","author":"Govindan","year":"2015","journal-title":"J Pharm Bioallied Sci"},{"key":"10.1016\/j.jacl.2025.12.003_bib0031","doi-asserted-by":"crossref","first-page":"782","DOI":"10.5152\/akd.2014.5826","article-title":"Rheumatoid factor mediates excess serum lipoprotein(a) for independent association with type 2 diabetes in men","volume":"15","author":"Onat","year":"2015","journal-title":"Anatol J Cardiol"},{"key":"10.1016\/j.jacl.2025.12.003_bib0032","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.3899\/jrheum.080928","article-title":"Conventional lipid profile and lipoprotein(a) concentrations in treated patients with rheumatoid arthritis","volume":"36","author":"Garc\u00eda-G\u00f3mez","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jacl.2025.12.003_bib0033","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1163\/156856904322858701","article-title":"Correlation between levels of lipoprotein (a) and disease activity score in patients with rheumatoid arthritis","volume":"16","author":"Taysi","year":"2004","journal-title":"Pain Clin"},{"key":"10.1016\/j.jacl.2025.12.003_bib0034","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/PL00011174","article-title":"Lipoprotein(a) and lipids in relation to inflammation in rheumatoid arthritis","volume":"19","author":"Lee","year":"2000","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jacl.2025.12.003_bib0035","first-page":"391","article-title":"Apolipoprotein(a) production and clearance are associated with plasma IL-6 and IL-18 levels, dependent on ethnicity","author":"Groenen","year":"2024","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2025.12.003_bib0036","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12944-016-0258-8","article-title":"The relationship between lp(a) and CVD outcomes: a systematic review","volume":"15","author":"Forbes","year":"2016","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.jacl.2025.12.003_bib0037","doi-asserted-by":"crossref","unstructured":"Farhat, H; Irfan, H; Muthiah, K; et al. Increased risk of cardiovascular diseases in rheumatoid arthritis: a systematic review. Cureus 14, e32308, doi:10.7759\/cureus.32308.","DOI":"10.7759\/cureus.32308"},{"key":"10.1016\/j.jacl.2025.12.003_bib0038","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00296-004-0438-0","article-title":"Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation","volume":"25","author":"Dursuno\u011flu","year":"2005","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jacl.2025.12.003_bib0039","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.3899\/jrheum.170029","article-title":"Cardiovascular risk factors and disease characteristics are consistently associated with arterial function in rheumatoid arthritis","volume":"44","author":"Gunter","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jacl.2025.12.003_bib0040","unstructured":"JACC Lipoprotein(a) and long-term cardiovascular risk in a multi-ethnic pooled prospective cohort Available online: https:\/\/www.jacc.org\/doi\/10.1016\/j.jacc.2024.02.031 (accessed 13 Sept. 2025)."},{"key":"10.1016\/j.jacl.2025.12.003_bib0041","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s13075-019-1975-y","article-title":"Subclinical and clinical atherosclerosis in rheumatoid arthritis: results from the 3-year, multicentre, prospective, observational GIRRCS (Gruppo Italiano Di Ricerca in Reumatologia Clinica e Sperimentale) study","volume":"21","author":"Ruscitti","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jacl.2025.12.003_bib0042","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13075-021-02542-7","article-title":"Disease activity influences the reclassification of rheumatoid arthritis into very high cardiovascular risk","volume":"23","author":"Ferraz-Amaro","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jacl.2025.12.003_bib0043","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.626842","article-title":"Dooming phagocyte responses: inflammatory effects of endogenous oxidized phospholipids","volume":"12","author":"Di Gioia","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.jacl.2025.12.003_bib0044","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40119-020-00177-4","article-title":"Lipoprotein(a) and cardiovascular disease prevention across diverse populations","volume":"9","author":"Pearson","year":"2020","journal-title":"Cardiol Ther"},{"key":"10.1016\/j.jacl.2025.12.003_bib0045","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/aje\/kwx087","article-title":"Human leukocyte antigen shared epitope and inflammation, cardiovascular disease, cancer, and mortality among postmenopausal women in the women\u2019s health initiative rheumatoid arthritis study","volume":"186","author":"Birru Talabi","year":"2017","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jacl.2025.12.003_bib0046","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1038\/s41467-018-04668-w","article-title":"Deep coverage whole genome sequences and plasma lipoprotein(a) in individuals of European and African ancestries","volume":"9","author":"Zekavat","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jacl.2025.12.003_bib0047","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1161\/CIRCULATIONAHA.122.059162","article-title":"Race and ethnicity stratification for polygenic risk score analyses may mask disparities in Hispanics","volume":"146","author":"Clarke","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2025.12.003_bib0048","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13075-022-02784-z","article-title":"The angiopoietin-like protein 4, apolipoprotein C3, and lipoprotein lipase axis is disrupted in patients with rheumatoid arthritis","volume":"24","author":"De Armas-Rillo","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jacl.2025.12.003_bib0049","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0281772","article-title":"Targeted proteomics using stable isotope labeled protein fragments enables precise and robust determination of total apolipoprotein(a) in Human plasma","volume":"18","author":"Hober","year":"2023","journal-title":"PLOS ONE"},{"key":"10.1016\/j.jacl.2025.12.003_bib0050","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.jtha.2023.12.019","article-title":"Antiphospholipid antibody solid phase\u2013Based assays: problems and proposed solutions for the 2023 ACR\/EULAR classification criteria for Antiphospholipid syndrome","volume":"22","author":"Huisman","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacl.2025.12.003_bib0051","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.trac.2017.07.009","article-title":"Quantification of lipoprotein profiles by nuclear magnetic resonance spectroscopy and multivariate data analysis","volume":"94","author":"Aru","year":"2017","journal-title":"TrAC Trends Anal Chem"},{"key":"10.1016\/j.jacl.2025.12.003_bib0052","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s40265-024-02046-z","article-title":"Therapeutic Potential of lipoprotein(a) inhibitors","volume":"84","author":"Nicholls","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.jacl.2025.12.003_bib0053","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11883-024-01187-6","article-title":"Lipoprotein(a): from causality to treatment","volume":"26","author":"Kronenberg","year":"2024","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.jacl.2025.12.003_bib0054","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1136\/annrheumdis-2017-212614","article-title":"Novel gene variants associated with cardiovascular disease in systemic Lupus erythematosus and rheumatoid arthritis","volume":"77","author":"Leonard","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jacl.2025.12.003_bib0055","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2016-eular.3844","article-title":"OP0212 Phospholipid transfer protein (PLTP): a link between inflammation and lipids in rheumatoid arthritis?","volume":"75","author":"Audo","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jacl.2025.12.003_bib0056","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.118.034311","article-title":"Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups","volume":"139","author":"Par\u00e9","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2025.12.003_bib0057","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13710","article-title":"Oxidized phospholipids and lipoprotein(a): an update","volume":"52","author":"Koutsogianni","year":"2022","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jacl.2025.12.003_bib0058","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193815","article-title":"PhosphoLipid transfer protein (PLTP) exerts a direct pro-inflammatory effect on rheumatoid arthritis (RA) fibroblasts-like-synoviocytes (FLS) independently of its lipid transfer activity","volume":"13","author":"Audo","year":"2018","journal-title":"PLOS ONE"},{"key":"10.1016\/j.jacl.2025.12.003_bib0059","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/biof.1890","article-title":"Oxidized phospholipids and lipoprotein-associated phospholipase A2 (Lp-PLA2) in atherosclerotic cardiovascular disease: an update","volume":"48","author":"Pantazi","year":"2022","journal-title":"BioFactors"},{"key":"10.1016\/j.jacl.2025.12.003_bib0060","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s11883-023-01141-y","article-title":"Treatment of lp(a): is it the future or are we ready today?","volume":"25","author":"Tselepis","year":"2023","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.jacl.2025.12.003_bib0061","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1136\/annrheumdis-2016-209744","article-title":"The role of non-invasive cardiovascular imaging in the assessment of cardiovascular risk in rheumatoid arthritis: where we are and where we need to Be","volume":"76","author":"Fent","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jacl.2025.12.003_bib0062","first-page":"15","article-title":"Association of lipoprotein (a) with coronary-computed tomography angiography\u2013Assessed high-risk coronary disease attributes and cardiovascular outcomes","author":"Dai","year":"2022","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jacl.2025.12.003_bib0063","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1001\/jamacardio.2024.1874","article-title":"Lipoprotein(a) and long-term plaque progression, low-density plaque, and pericoronary inflammation","volume":"9","author":"Nurmohamed","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacl.2025.12.003_bib0064","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024870","article-title":"Lipoprotein(a) and subclinical vascular and valvular calcification on cardiac computed tomography: the atherosclerosis risk in communities study","volume":"11","author":"Obisesan","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2025.12.003_bib0065","doi-asserted-by":"crossref","first-page":"656","DOI":"10.3390\/biomedicines10030656","article-title":"on behalf of the Brisighella Heart Study Group lipoprotein(a) serum levels predict pulse wave velocity in subjects in primary prevention for cardiovascular disease with large apo(a) isoforms: data from the Brisighella Heart Study","volume":"10","author":"Cicero","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.jacl.2025.12.003_bib0066","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12944-021-01438-4","article-title":"Lipoprotein-associated phospholipase A2 levels, endothelial dysfunction and arterial stiffness in patients with stable coronary artery disease","volume":"20","author":"Mourouzis","year":"2021","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.jacl.2025.12.003_bib0067","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2020.511391","article-title":"Imaging atherosclerosis by PET, with emphasis on the role of FDG and NaF as potential biomarkers for this disorder","volume":"11","author":"Mayer","year":"2020","journal-title":"Front Physiol"},{"key":"10.1016\/j.jacl.2025.12.003_bib0068","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13075-024-03352-3","article-title":"Impact of RA treatment strategies on lipids and vascular inflammation in rheumatoid arthritis: a secondary analysis of the TARGET randomized active comparator trial","volume":"26","author":"Liao","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jacl.2025.12.003_bib0069","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003489","article-title":"Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT Register","volume":"9","author":"Meissner","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.jacl.2025.12.003_bib0070","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s13075-022-02930-7","article-title":"Methotrexate improves endothelial function in early rheumatoid arthritis patients after 3 months of treatment","volume":"24","author":"Cafaro","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jacl.2025.12.003_bib0071","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3899\/jrheum.201415","article-title":"Methotrexate and cardiovascular disease in patients with rheumatoid arthritis: insights and novel speculations","volume":"48","author":"Kremer","year":"2021","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jacl.2025.12.003_bib0072","first-page":"415","article-title":"Serum levels of lipoprotein(a) and E-selectin are reduced in rheumatoid arthritis patients treated with methotrexate or methotrexate in combination with TNF-\u03b1-inhibitor","volume":"31","author":"Hjeltnes","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jacl.2025.12.003_bib0073","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1111\/bph.13805","article-title":"Vascular inflammation and low-density lipoproteins: is cholesterol the link? A lesson from the clinical trials","volume":"174","author":"Catapano","year":"2017","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jacl.2025.12.003_bib0074","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2025.12.003_bib0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220178","article-title":"Cardiovascular safety of Tocilizumab: a systematic review and network meta-analysis","volume":"14","author":"Castagn\u00e9","year":"2019","journal-title":"PLOS ONE"},{"key":"10.1016\/j.jacl.2025.12.003_bib0076","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.3390\/jcm9072157","article-title":"Anti-atherogenic modification of serum lipoprotein function in patients with rheumatoid arthritis after Tocilizumab treatment, a pilot study","volume":"9","author":"Greco","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacl.2025.12.003_bib0077","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.765749","article-title":"Improvements in high-density lipoprotein quantity and quality contribute to the cardiovascular benefits by anti-tumor necrosis factor therapies in rheumatoid arthritis: a systemic review and meta-analysis","volume":"8","author":"Luo","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacl.2025.12.003_bib0078","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1136\/annrheumdis-2011-201148","article-title":"Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis","volume":"71","author":"Da\u00efen","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jacl.2025.12.003_bib0079","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-000897","article-title":"Comparative effect of tumour necrosis factor inhibitors versus other biological agents on cardiovascular risk-associated biomarkers in patients with rheumatoid arthritis","volume":"5","author":"Virone","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.jacl.2025.12.003_bib0080","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/annrheumdis-2014-eular.3030","article-title":"OP0165 Changes in lipoprotein(A) after treatment with Tocilizumab (TCZ), Adalimumab (ADA), and methotrexate (MTX) in patients with rheumatoid arthritis (RA)","volume":"73","author":"Gabay","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jacl.2025.12.003_bib0081","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.athplu.2023.09.001","article-title":"Lipoprotein(a), interleukin-6 inhibitors, and atherosclerotic cardiovascular disease: is there an association?","volume":"54","author":"Makris","year":"2023","journal-title":"Atheroscler Plus"},{"key":"10.1016\/j.jacl.2025.12.003_bib0082","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1194\/jlr.P052209","article-title":"IL-6 blockade by Monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans","volume":"56","author":"M\u00fcller","year":"2015","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2025.12.003_bib0083","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/annrheumdis-2013-204345","article-title":"Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study","volume":"74","author":"McInnes","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jacl.2025.12.003_bib0084","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.005038","article-title":"Interleukin 6 inhibition and coronary artery disease in a high-risk population: a prospective community-based clinical study","volume":"6","author":"Bacchiega","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2025.12.003_bib0085","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.905941","article-title":"Familial hypercholesterolemia and elevated lipoprotein(a): cascade testing and other implications for contextual models of care","volume":"13","author":"Loh","year":"2022","journal-title":"Front Genet"},{"key":"10.1016\/j.jacl.2025.12.003_bib0086","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1172\/JCI109813","article-title":"Turnover of lipoprotein(a) in man","volume":"65","author":"Krempler","year":"1980","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacl.2025.12.003_bib0087","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028456","article-title":"Interleukin (IL-6) Immunotherapy","volume":"10","author":"Tanaka","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.jacl.2025.12.003_bib0088","doi-asserted-by":"crossref","first-page":"750","DOI":"10.3390\/ph16050750","article-title":"Effects of lipid-modifying and other drugs on lipoprotein(a) levels\u2014Potent clinical implications","volume":"16","author":"Koutsogianni","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jacl.2025.12.003_bib0089","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1093\/eurheartj\/ehy311","article-title":"PCSK9 Inhibition and lp(a) reduction: another piece of the puzzle?","volume":"39","author":"Pirillo","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.12.003_bib0090","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3899\/jrheum.180726","article-title":"Cardiovascular event risk in rheumatoid arthritis compared with type 2 diabetes: a 15-year longitudinal study","volume":"47","author":"Agca","year":"2020","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jacl.2025.12.003_bib0091","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.3390\/jcm11102704","article-title":"Cardiovascular disease risk in rheumatoid arthritis Anno 2022","volume":"11","author":"Dijkshoorn","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacl.2025.12.003_bib0092","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/eurjpc\/zwab171","article-title":"Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis","volume":"29","author":"de Boer","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2025.12.003_bib0093","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000035088","article-title":"The efficacy of statins in the treatment of rheumatoid arthritis: a systematic review and meta-analysis","volume":"102","author":"Ren","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jacl.2025.12.003_bib0094","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1001\/jamacardio.2022.0987","article-title":"Lipoprotein(a) and its significance in cardiovascular disease: a review","volume":"7","author":"Duarte Lau","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacl.2025.12.003_bib0095","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1177\/2047487319833504","article-title":"PCSK9 Monoclonal antibodies and lipoprotein apheresis for lowering lipoprotein(a): making choices in an era of RNA-based therapies","volume":"26","author":"Ruscica","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2025.12.003_bib0096","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1194\/jlr.P065334","article-title":"PCSK9 Inhibition-mediated reduction in lp(a) with Evolocumab: an analysis of 10 clinical trials and the LDL receptor\u2019s role","volume":"57","author":"Raal","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2025.12.003_bib0097","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O\u2019Donoghue","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2025.12.003_bib0098","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3389\/fcvm.2020.00088","article-title":"The evolving understanding and approach to residual cardiovascular risk management","volume":"7","author":"Dhindsa","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacl.2025.12.003_bib0099","doi-asserted-by":"crossref","first-page":"27","DOI":"10.5114\/reum.2019.83236","article-title":"Cardiac and vascular complications in rheumatoid arthritis","volume":"57","author":"Rawla","year":"2019","journal-title":"Reumatologia"},{"key":"10.1016\/j.jacl.2025.12.003_bib0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2024.102586","article-title":"Elevated lipoprotein(a) levels: a crucial determinant of cardiovascular disease risk and target for emerging therapies","volume":"49","author":"Afzal","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.jacl.2025.12.003_bib0101","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/phar.2851","article-title":"Role of lipoprotein(a) in atherosclerotic cardiovascular disease: a review of current and emerging therapies","volume":"43","author":"Alhomoud","year":"2023","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"10.1016\/j.jacl.2025.12.003_bib0102","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.clinthera.2023.07.008","article-title":"The promise of PCSK9 and lipoprotein(a) as targets for gene silencing therapies","volume":"45","author":"Chan","year":"2023","journal-title":"Clin Ther"},{"key":"10.1016\/j.jacl.2025.12.003_bib0103","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.3390\/ph15121573","article-title":"Targeted treatment against lipoprotein (a) : the coming breakthrough in lipid lowering therapy","volume":"15","author":"Sosnowska","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jacl.2025.12.003_bib0104","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/ckj\/sfaa001","article-title":"Pelacarsen for lowering lipoprotein(a): implications for patients with chronic kidney disease","volume":"13","author":"Fernandez-Prado","year":"2020","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.jacl.2025.12.003_bib0105","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/17512433.2023.2174524","article-title":"Strategies for lowering lipoprotein(a): a spotlight on novel pharmacological treatments","volume":"16","author":"Polychronopoulos","year":"2023","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.jacl.2025.12.003_bib0106","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O\u2019Donoghue","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2025.12.003_bib0107","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11883-020-0826-2","article-title":"Nucleic acid\u2013Based therapies for atherosclerosis","volume":"22","author":"M\u00e4kinen","year":"2020","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.jacl.2025.12.003_bib0108","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1021\/acsptsci.4c00067","article-title":"Unveiling novel drug targets and emerging therapies for rheumatoid arthritis: a comprehensive review","volume":"7","author":"Khokhar","year":"2024","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.jacl.2025.12.003_bib0109","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.1012661","article-title":"Disease-modifying anti-rheumatic drugs improve the cardiovascular profile in patients with rheumatoid arthritis","volume":"9","author":"Giachi","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacl.2025.12.003_bib0110","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.amjmed.2023.09.004","article-title":"The cardiovascular burden of rheumatoid arthritis \u2013 Implications for treatment","volume":"136","author":"Schattner","year":"2023","journal-title":"Am J Med"},{"key":"10.1016\/j.jacl.2025.12.003_bib0111","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1161\/CIRCULATIONAHA.124.070081","article-title":"Precision medicine for cardiovascular prevention and population health: a bridge too far?","volume":"150","author":"Giugni","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2025.12.003_bib0112","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1146\/annurev-pharmtox-031023-100609","article-title":"LP(a): structure, genetics, associated cardiovascular risk, and emerging therapeutics","volume":"64","author":"Tasdighi","year":"2024","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.jacl.2025.12.003_bib0113","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1373\/clinchem.2017.280172","article-title":"Partitioning the genetic architecture of plasma lipoprotein(a) and Kringle IV type 2 repeats: implications for therapeutic lowering","volume":"63","author":"Lawler","year":"2017","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacl.2025.12.003_bib0114","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1001\/jama.2022.5333","article-title":"The potential clinical benefit of lowering lipoprotein(a)","volume":"327","author":"Ference","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2025.12.003_bib0115","doi-asserted-by":"crossref","DOI":"10.1111\/eci.14254","article-title":"New insights into the therapeutic options to lower lipoprotein(a)","volume":"54","author":"Baragetti","year":"2024","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jacl.2025.12.003_bib0116","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1080\/10408363.2023.2229915","article-title":"Lipoprotein(a): a genetically determined risk factor for cardiovascular disease","volume":"60","author":"Marcovina","year":"2023","journal-title":"Crit Rev Clin Lab Sci"},{"key":"10.1016\/j.jacl.2025.12.003_bib0117","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2023.101746","article-title":"Supporting evidence for lipoprotein(a) measurements in clinical practice","volume":"37","author":"Matveyenko","year":"2023","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.jacl.2025.12.003_bib0118","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.3390\/jcm11102704","article-title":"Cardiovascular disease risk in rheumatoid arthritis Anno 2022","volume":"11","author":"Dijkshoorn","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacl.2025.12.003_bib0119","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1001\/jamacardio.2022.4063","article-title":"Primary prevention management of elevated lipoprotein(a)","volume":"8","author":"Agarwala","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacl.2025.12.003_bib0120","doi-asserted-by":"crossref","first-page":"ehae666","DOI":"10.1093\/eurheartj\/ehae666.2709","article-title":"Comparison of cardiovascular disease risk assessment tools in primary prevention patients with raised lipoprotein(a)","volume":"45","author":"Carlton","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.12.003_bib0121","doi-asserted-by":"crossref","first-page":"ehae666","DOI":"10.1093\/eurheartj\/ehae666.2734","article-title":"A sex-related analysis on the influence of lipoprotein(a) on primary cardiovascular disease prevention and its interplay with traditional lipid markers: results from a 20-year cohort study","volume":"45","author":"Giannakopoulou","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.12.003_bib0122","article-title":"Novel method for predicting lp(a) from genomic testing identifies ASCVD risk across a diverse cohort","volume":"10","author":"Telis","year":"2025","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.jacl.2025.12.003_bib0123","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154706","article-title":"Lipoprotein (a) and coronary artery calcification: prospective study assessing interactions with other risk factors","volume":"116","author":"Ong","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.jacl.2025.12.003_bib0124","first-page":"e596","article-title":"2019 ACC\/AHA Guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on clinical Practice Guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2025.12.003_bib0125","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS Guidelines for the Management of Dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.12.003_bib0126","doi-asserted-by":"crossref","first-page":"zwae175","DOI":"10.1093\/eurjpc\/zwae175.297","article-title":"Lp(a) and vascular inflammation: data from perivascular fat attenuation index measurements","volume":"31","author":"Simantiris","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2025.12.003_bib0127","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehac544.2307","article-title":"C-reactive protein as a possible modifier of lipoprotein(a)-related risk for coronary heart disease in Europe: results from the BiomarCARE Project","volume":"43","author":"Arnold","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.12.003_bib0128","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241713622","article-title":"Novel pharmacological therapies for the management of hyperlipoproteinemia(a)","volume":"24","author":"Kosmas","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jacl.2025.12.003_bib0129","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10557-016-6654-5","article-title":"Future directions to establish lipoprotein(a) as a treatment for atherosclerotic cardiovascular disease","volume":"30","author":"Stein","year":"2016","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacl.2025.12.003_bib0130","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/art.42828","article-title":"Rounding third base and heading home\u201d: arthritis & rheumatology in 2024","volume":"76","author":"Solomon","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jacl.2025.12.003_bib0131","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/eurjpc\/zwae032","article-title":"Lipoprotein(a) and cardiovascular disease: sifting the evidence to guide future research","volume":"31","author":"Kamstrup","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2025.12.003_bib0132","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11883-019-0803-9","article-title":"Looking at lp(a) and related cardiovascular risk: from scientific evidence and clinical practice","volume":"21","author":"Stulnig","year":"2019","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.jacl.2025.12.003_bib0133","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/clinchem\/hvac094","article-title":"The curious case of synergy between lipoprotein (a) coronary calcification, and cardiovascular disease risk","volume":"68","author":"Almarzooq","year":"2022","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacl.2025.12.003_bib0134","doi-asserted-by":"crossref","first-page":"583","DOI":"10.5551\/jat.RV17034","article-title":"Lipoprotein(a) as an old and new causal risk factor of atherosclerotic cardiovascular disease","volume":"26","author":"Tada","year":"2019","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jacl.2025.12.003_bib0135","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41392-022-00955-7","article-title":"Inflammation and atherosclerosis: signaling pathways and therapeutic intervention","volume":"7","author":"Kong","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jacl.2025.12.003_bib0136","first-page":"11","article-title":"Lipoprotein(a), immunity, and inflammation in polyvascular atherosclerotic disease","volume":"8","author":"Tmoyan","year":"2021","journal-title":"J Cardiovasc Dev Dis"},{"key":"10.1016\/j.jacl.2025.12.003_bib0137","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2025.03.019","article-title":"Design and rationale of Lp(a)HORIZON trial: assessing the effect of lipoprotein(a) Lowering with pelacarsen on major cardiovascular events in patients with CVD and elevated Lp(a)","volume":"287","author":"Cho","year":"2025","journal-title":"Am Heart J"},{"issue":"25","key":"10.1016\/j.jacl.2025.12.003_bib0138","first-page":"00322","article-title":"Pelacarsen: mechanism of action and lp(a)-lowering effect","volume":"S1933-2874","author":"Bhatia","year":"2025","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.12.003_bib0139","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jacc.2024.05.058","article-title":"The off-treatment effects of Olpasiran on lipoprotein(a) lowering: OCEAN(a)-DOSE extension period results","volume":"84","author":"O\u2019Donoghue","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2025.12.003_bib0140","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1001\/jama.2024.21957","article-title":"Zerlasiran-a small-interfering RNA targeting lipoprotein(a): a phase 2 randomized clinical trial","volume":"332","author":"Nissen","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2025.12.003_bib0141","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.025551","article-title":"Network meta-analysis of randomized trials evaluating the comparative efficacy of lipid-lowering therapies added to maximally tolerated statins for the reduction of low-density lipoprotein cholesterol","volume":"11","author":"Toth","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2025.12.003_bib0142","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCULATIONAHA.124.069210","article-title":"Lipoprotein(a) as a pharmacological target: premises, promises, and prospects","volume":"151","author":"Greco","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2025.12.003_bib0143","doi-asserted-by":"crossref","first-page":"e304","DOI":"10.1161\/ATV.0000000000000177","article-title":"Lipoprotein apheresis: utility, outcomes, and implementation in clinical practice: A scientific statement from the American Heart Association","volume":"44","author":"Gianos","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2025.12.003_bib0144","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehae666.2857","article-title":"Effects of lipid-lowering therapies on lipoprotein(a) levels in patients with dyslipidemia: a systematic review and network meta-analysis of 64 randomised controlled trials","volume":"45","author":"Loh","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.12.003_bib0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.athplu.2023.09.001","article-title":"Lipoprotein(a), interleukin-6 inhibitors, and atherosclerotic cardiovascular disease: is there an association?","volume":"54","author":"Makris","year":"2023","journal-title":"Atheroscler Plus"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425005252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425005252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T09:02:17Z","timestamp":1773219737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287425005252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":145,"alternative-id":["S1933287425005252"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2025.12.003","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipoprotein(a) at the crossroads of inflammation and atherosclerosis in rheumatoid arthritis: A narrative review","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2025.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}